BCR-ABL tyrosine kinase inhibitors (BCR-ABL TKIs) have improved the survival of patients with chronic myeloid leukemia. Growing evidence suggest that cancer therapeutics-related cardiac dysfunction has become an important serious adverse event. BCR-ABL TKIs has been also reported to induce left ventricular dysfunction and cardiac failure in clinical settings. We have previously developed an imaging-based contractility assay using human iPS cell-derived cardiomyocytes (hiPSC-CMs). Here we investigated the effect of BCR-ABL TKIs on contractility of hiPSC-CMs using the contractility assay. We used iCell cardiomyocytes 2.0 (Fujifilm Cellular Dynamics International). Motion analysis was performed using cell motion imaging system (SI8000, Sony). We found that nilotinib and imatinib decreased contraction velocity of hiPSC-CMs by chronic treatment. In contrast, bosutinib had little effect on contraction velocity. To confirm the in vitro data, we analyzed the cardiotoxicity risk of BCR-ABL TKIs by the real-world pharmacovigilance data, which were analyzed using FDA Adverse Events Reporting System (FAERS). We found that hiPSC-CMs data was correlated with FAERS signals. In conclusion, these results suggest that imaging-based contractility assessment using hiPSC-CMs is a useful platform to assess cancer therapeutics-related cardiac dysfunction in human.